newsfilter
← Latest News
GlobeNewswire·

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data Evaluating Dose 2, 50% lower than